A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for STARGARDT DISEASE

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Mar 2025 According to an Ocugen media release, company announced that the European Commission has provided a positive opinion from the European Medicines Agencys (EMA) Committee for Advanced Therapies (CAT) for OCU410 and OCU410ST Advanced Therapy Medicinal Product (ATMP) classification.
27 Feb 2025 Results presented in an Ocugen media release
11 Dec 2024 According to an Ocugen media release, the company will share more data about these two exciting programs the Phase 3 OCU400 liMeliGhT clinical trial for RP and Phase 1/2 OCU410ST GARDian clinical trial for Stargardt disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com